1. Home
  2. STDN vs XNCR Comparison

STDN vs XNCR Comparison

Compare STDN & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Standard Nuclear Inc. Class A Common Stock

STDN

Standard Nuclear Inc. Class A Common Stock

N/A

Current Price

$11.56

Market Cap

1.9B

ML Signal

N/A

Logo Xencor Inc.

XNCR

Xencor Inc.

N/A

Current Price

$29.62

Market Cap

2.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
STDN
XNCR
Founded
2024
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
2.0B
IPO Year
2026
2013

Fundamental Metrics

Financial Performance
Metric
STDN
XNCR
Price
$11.56
$29.62
Analyst Decision
Strong Buy
Buy
Analyst Count
9
14
Target Price
$17.25
★ $41.58
AVG Volume (30 Days)
265.4K
★ 1.6M
Earning Date
11-12-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 65.36
EPS
★ N/A
N/A
Revenue
N/A
★ $125,576,000.00
Revenue This Year
$439.23
$18.52
Revenue Next Year
$259.21
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 13.65
52 Week Low
$7.05
$10.38
52 Week High
$17.34
$33.60

Technical Indicators

Market Signals
Indicator
STDN
XNCR
Relative Strength Index (RSI) 41.28 64.64
Support Level $11.42 $22.80
Resistance Level $13.73 $30.61
Average True Range (ATR) 0.81 1.68
MACD -0.07 0.55
Stochastic Oscillator 10.06 63.20

Price Performance

Historical Comparison
STDN
XNCR

About STDN Standard Nuclear Inc. Class A Common Stock

Standard Nuclear Inc is an independent advanced nuclear fuel company. The company designs, engineers, and manufactures advanced nuclear fuels, with a primary focus on TRISO fuel for advanced reactors. Its operations include industrial-scale TRISO fuel manufacturing and the development of fuel for advanced reactors that utilize TRISO fuel. The company operates in a single operating and reportable segment, as it is engaged in a single business activity of TRISO production. It derives revenue from fuel development and services agreements. Geographically, the maximum revenue is generated from the United States.

About XNCR Xencor Inc.

Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.

Share on Social Networks: